The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C
Aim. To evaluate the efficiency and safety of two eradication therapy (ET) regimens for Helicobacter pylori infection in patients with concomitant chronic hepatitis C (CHC) in relation to the stage of liver fibrosis (LF). Subjects and methods. A prospective clinical trial was conducted in parallel g...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
D N Andreev [verfasserIn] I V Maev [verfasserIn] Yu A Kucheryavyi [verfasserIn] D T Dicheva [verfasserIn] E V Partsvania-vinogradova [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2016 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Терапевтический архив - "Consilium Medicum" Publishing house, 2018, 88(2016), 4, Seite 75-81 |
|---|---|
| Übergeordnetes Werk: |
volume:88 ; year:2016 ; number:4 ; pages:75-81 |
| Links: |
|---|
| Katalog-ID: |
DOAJ045754519 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ045754519 | ||
| 003 | DE-627 | ||
| 005 | 20230308095232.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2016 xx |||||o 00| ||rus c | ||
| 035 | |a (DE-627)DOAJ045754519 | ||
| 035 | |a (DE-599)DOAJ6ebba4cee6dc49899868fa5ccff77a9b | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 0 | |a D N Andreev |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Aim. To evaluate the efficiency and safety of two eradication therapy (ET) regimens for Helicobacter pylori infection in patients with concomitant chronic hepatitis C (CHC) in relation to the stage of liver fibrosis (LF). Subjects and methods. A prospective clinical trial was conducted in parallel groups. Group 1 included 50 HCV-negative patients with H. pylori-associated peptic ulcer of the stomach or duodenum; Group 2 consisted of 50 HCV-positive patients with H. pylori-associated peptic ulcer of the stomach or duodenum concurrent with CHC. Each group was divided in 2 subgroups according to the used triple ET (a proton pump inhibitor (PPI) in a standard dose + amoxicillin 1000 mg twice daily + clarithromycin 500 mg twice daily for 10 days) or sequential therapy (PPI in a standard dose + amoxicillin 1000 mg twice daily within the first 5 days and then PPI in a standard dose + clarithromycin 500 mg twice daily + metronidazole 500 mg twice daily for the next 5 days). LF was assessed using indirect elastometry. The efficiency of ET was evaluated by a breath test (after 4 weeks) and an analysis depending on intention-to-treat (ITT) and per-protocol (PP) treatments. A patients recorded adverse events in specially developed diaries. Results. The efficiency of ET was 74% (ITT) and 80.4% (PP) in Group 1 and 76 (ITT) and 79.1% (PP) in Group 2. Both groups displayed a tendency towards an 11.9—12.4% increase in the efficiency of the sequential therapy versus the classical triple (PP) one. The rate of totally found side effects was 20% in Group 1 and 28% in Group 2. During sequential therapy, the rate of side effects was lower than that during the classical one. The efficiency of ET did not significantly depend on the stage of LF. Only the presence of concomitant type 2 diabetes mellitus and the use of macrolides (12 months before treatment) significantly lowered the efficiency of ET (OR 0,21; 95% CI 0,06—0,69, p=0,0102 and OR 0,27 95% CI 0,08—0,9, p=0,0342). LF regardless of its magnitude significantly determined the risk of adverse events during ET (OR 3,33 95% CI 1,19—9,31, p=0,0217). A group at the highest risk of adverse events included patients with liver cirrhosis (OR 4,87; 95% CI 1,01—23,5, p=0,0492). Conclusion. It is appropriate to prescribe a sequential ET regimen as more effective and safe for patients with concomitant CHC during therapy for H. pylori infection-associated diseases. LF increases the risk of adverse events during ET. | ||
| 650 | 4 | |a helicobacter pylori | |
| 650 | 4 | |a peptic ulcer | |
| 650 | 4 | |a hcv | |
| 650 | 4 | |a hepatitis c | |
| 650 | 4 | |a liver fibrosis | |
| 650 | 4 | |a liver cirrhosis | |
| 650 | 4 | |a anti-helicobacter pylori therapy | |
| 650 | 4 | |a adverse events | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a I V Maev |e verfasserin |4 aut | |
| 700 | 0 | |a Yu A Kucheryavyi |e verfasserin |4 aut | |
| 700 | 0 | |a D T Dicheva |e verfasserin |4 aut | |
| 700 | 0 | |a E V Partsvania-vinogradova |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Терапевтический архив |d "Consilium Medicum" Publishing house, 2018 |g 88(2016), 4, Seite 75-81 |w (DE-627)1760620270 |x 23095342 |7 nnns |
| 773 | 1 | 8 | |g volume:88 |g year:2016 |g number:4 |g pages:75-81 |
| 856 | 4 | 0 | |u https://doaj.org/article/6ebba4cee6dc49899868fa5ccff77a9b |z kostenfrei |
| 856 | 4 | 0 | |u https://ter-arkhiv.ru/0040-3660/article/viewFile/31983/pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/0040-3660 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2309-5342 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 88 |j 2016 |e 4 |h 75-81 | ||
| author_variant |
d n a dna i v m ivm y a k yak d t d dtd e v p v evpv |
|---|---|
| matchkey_str |
article:23095342:2016----::hefcecadaeyfnieioatryoihrpiptetwtc |
| hierarchy_sort_str |
2016 |
| publishDate |
2016 |
| allfields |
(DE-627)DOAJ045754519 (DE-599)DOAJ6ebba4cee6dc49899868fa5ccff77a9b DE-627 ger DE-627 rakwb rus D N Andreev verfasserin aut The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To evaluate the efficiency and safety of two eradication therapy (ET) regimens for Helicobacter pylori infection in patients with concomitant chronic hepatitis C (CHC) in relation to the stage of liver fibrosis (LF). Subjects and methods. A prospective clinical trial was conducted in parallel groups. Group 1 included 50 HCV-negative patients with H. pylori-associated peptic ulcer of the stomach or duodenum; Group 2 consisted of 50 HCV-positive patients with H. pylori-associated peptic ulcer of the stomach or duodenum concurrent with CHC. Each group was divided in 2 subgroups according to the used triple ET (a proton pump inhibitor (PPI) in a standard dose + amoxicillin 1000 mg twice daily + clarithromycin 500 mg twice daily for 10 days) or sequential therapy (PPI in a standard dose + amoxicillin 1000 mg twice daily within the first 5 days and then PPI in a standard dose + clarithromycin 500 mg twice daily + metronidazole 500 mg twice daily for the next 5 days). LF was assessed using indirect elastometry. The efficiency of ET was evaluated by a breath test (after 4 weeks) and an analysis depending on intention-to-treat (ITT) and per-protocol (PP) treatments. A patients recorded adverse events in specially developed diaries. Results. The efficiency of ET was 74% (ITT) and 80.4% (PP) in Group 1 and 76 (ITT) and 79.1% (PP) in Group 2. Both groups displayed a tendency towards an 11.9—12.4% increase in the efficiency of the sequential therapy versus the classical triple (PP) one. The rate of totally found side effects was 20% in Group 1 and 28% in Group 2. During sequential therapy, the rate of side effects was lower than that during the classical one. The efficiency of ET did not significantly depend on the stage of LF. Only the presence of concomitant type 2 diabetes mellitus and the use of macrolides (12 months before treatment) significantly lowered the efficiency of ET (OR 0,21; 95% CI 0,06—0,69, p=0,0102 and OR 0,27 95% CI 0,08—0,9, p=0,0342). LF regardless of its magnitude significantly determined the risk of adverse events during ET (OR 3,33 95% CI 1,19—9,31, p=0,0217). A group at the highest risk of adverse events included patients with liver cirrhosis (OR 4,87; 95% CI 1,01—23,5, p=0,0492). Conclusion. It is appropriate to prescribe a sequential ET regimen as more effective and safe for patients with concomitant CHC during therapy for H. pylori infection-associated diseases. LF increases the risk of adverse events during ET. helicobacter pylori peptic ulcer hcv hepatitis c liver fibrosis liver cirrhosis anti-helicobacter pylori therapy adverse events Medicine R I V Maev verfasserin aut Yu A Kucheryavyi verfasserin aut D T Dicheva verfasserin aut E V Partsvania-vinogradova verfasserin aut In Терапевтический архив "Consilium Medicum" Publishing house, 2018 88(2016), 4, Seite 75-81 (DE-627)1760620270 23095342 nnns volume:88 year:2016 number:4 pages:75-81 https://doaj.org/article/6ebba4cee6dc49899868fa5ccff77a9b kostenfrei https://ter-arkhiv.ru/0040-3660/article/viewFile/31983/pdf kostenfrei https://doaj.org/toc/0040-3660 Journal toc kostenfrei https://doaj.org/toc/2309-5342 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 88 2016 4 75-81 |
| spelling |
(DE-627)DOAJ045754519 (DE-599)DOAJ6ebba4cee6dc49899868fa5ccff77a9b DE-627 ger DE-627 rakwb rus D N Andreev verfasserin aut The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To evaluate the efficiency and safety of two eradication therapy (ET) regimens for Helicobacter pylori infection in patients with concomitant chronic hepatitis C (CHC) in relation to the stage of liver fibrosis (LF). Subjects and methods. A prospective clinical trial was conducted in parallel groups. Group 1 included 50 HCV-negative patients with H. pylori-associated peptic ulcer of the stomach or duodenum; Group 2 consisted of 50 HCV-positive patients with H. pylori-associated peptic ulcer of the stomach or duodenum concurrent with CHC. Each group was divided in 2 subgroups according to the used triple ET (a proton pump inhibitor (PPI) in a standard dose + amoxicillin 1000 mg twice daily + clarithromycin 500 mg twice daily for 10 days) or sequential therapy (PPI in a standard dose + amoxicillin 1000 mg twice daily within the first 5 days and then PPI in a standard dose + clarithromycin 500 mg twice daily + metronidazole 500 mg twice daily for the next 5 days). LF was assessed using indirect elastometry. The efficiency of ET was evaluated by a breath test (after 4 weeks) and an analysis depending on intention-to-treat (ITT) and per-protocol (PP) treatments. A patients recorded adverse events in specially developed diaries. Results. The efficiency of ET was 74% (ITT) and 80.4% (PP) in Group 1 and 76 (ITT) and 79.1% (PP) in Group 2. Both groups displayed a tendency towards an 11.9—12.4% increase in the efficiency of the sequential therapy versus the classical triple (PP) one. The rate of totally found side effects was 20% in Group 1 and 28% in Group 2. During sequential therapy, the rate of side effects was lower than that during the classical one. The efficiency of ET did not significantly depend on the stage of LF. Only the presence of concomitant type 2 diabetes mellitus and the use of macrolides (12 months before treatment) significantly lowered the efficiency of ET (OR 0,21; 95% CI 0,06—0,69, p=0,0102 and OR 0,27 95% CI 0,08—0,9, p=0,0342). LF regardless of its magnitude significantly determined the risk of adverse events during ET (OR 3,33 95% CI 1,19—9,31, p=0,0217). A group at the highest risk of adverse events included patients with liver cirrhosis (OR 4,87; 95% CI 1,01—23,5, p=0,0492). Conclusion. It is appropriate to prescribe a sequential ET regimen as more effective and safe for patients with concomitant CHC during therapy for H. pylori infection-associated diseases. LF increases the risk of adverse events during ET. helicobacter pylori peptic ulcer hcv hepatitis c liver fibrosis liver cirrhosis anti-helicobacter pylori therapy adverse events Medicine R I V Maev verfasserin aut Yu A Kucheryavyi verfasserin aut D T Dicheva verfasserin aut E V Partsvania-vinogradova verfasserin aut In Терапевтический архив "Consilium Medicum" Publishing house, 2018 88(2016), 4, Seite 75-81 (DE-627)1760620270 23095342 nnns volume:88 year:2016 number:4 pages:75-81 https://doaj.org/article/6ebba4cee6dc49899868fa5ccff77a9b kostenfrei https://ter-arkhiv.ru/0040-3660/article/viewFile/31983/pdf kostenfrei https://doaj.org/toc/0040-3660 Journal toc kostenfrei https://doaj.org/toc/2309-5342 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 88 2016 4 75-81 |
| allfields_unstemmed |
(DE-627)DOAJ045754519 (DE-599)DOAJ6ebba4cee6dc49899868fa5ccff77a9b DE-627 ger DE-627 rakwb rus D N Andreev verfasserin aut The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To evaluate the efficiency and safety of two eradication therapy (ET) regimens for Helicobacter pylori infection in patients with concomitant chronic hepatitis C (CHC) in relation to the stage of liver fibrosis (LF). Subjects and methods. A prospective clinical trial was conducted in parallel groups. Group 1 included 50 HCV-negative patients with H. pylori-associated peptic ulcer of the stomach or duodenum; Group 2 consisted of 50 HCV-positive patients with H. pylori-associated peptic ulcer of the stomach or duodenum concurrent with CHC. Each group was divided in 2 subgroups according to the used triple ET (a proton pump inhibitor (PPI) in a standard dose + amoxicillin 1000 mg twice daily + clarithromycin 500 mg twice daily for 10 days) or sequential therapy (PPI in a standard dose + amoxicillin 1000 mg twice daily within the first 5 days and then PPI in a standard dose + clarithromycin 500 mg twice daily + metronidazole 500 mg twice daily for the next 5 days). LF was assessed using indirect elastometry. The efficiency of ET was evaluated by a breath test (after 4 weeks) and an analysis depending on intention-to-treat (ITT) and per-protocol (PP) treatments. A patients recorded adverse events in specially developed diaries. Results. The efficiency of ET was 74% (ITT) and 80.4% (PP) in Group 1 and 76 (ITT) and 79.1% (PP) in Group 2. Both groups displayed a tendency towards an 11.9—12.4% increase in the efficiency of the sequential therapy versus the classical triple (PP) one. The rate of totally found side effects was 20% in Group 1 and 28% in Group 2. During sequential therapy, the rate of side effects was lower than that during the classical one. The efficiency of ET did not significantly depend on the stage of LF. Only the presence of concomitant type 2 diabetes mellitus and the use of macrolides (12 months before treatment) significantly lowered the efficiency of ET (OR 0,21; 95% CI 0,06—0,69, p=0,0102 and OR 0,27 95% CI 0,08—0,9, p=0,0342). LF regardless of its magnitude significantly determined the risk of adverse events during ET (OR 3,33 95% CI 1,19—9,31, p=0,0217). A group at the highest risk of adverse events included patients with liver cirrhosis (OR 4,87; 95% CI 1,01—23,5, p=0,0492). Conclusion. It is appropriate to prescribe a sequential ET regimen as more effective and safe for patients with concomitant CHC during therapy for H. pylori infection-associated diseases. LF increases the risk of adverse events during ET. helicobacter pylori peptic ulcer hcv hepatitis c liver fibrosis liver cirrhosis anti-helicobacter pylori therapy adverse events Medicine R I V Maev verfasserin aut Yu A Kucheryavyi verfasserin aut D T Dicheva verfasserin aut E V Partsvania-vinogradova verfasserin aut In Терапевтический архив "Consilium Medicum" Publishing house, 2018 88(2016), 4, Seite 75-81 (DE-627)1760620270 23095342 nnns volume:88 year:2016 number:4 pages:75-81 https://doaj.org/article/6ebba4cee6dc49899868fa5ccff77a9b kostenfrei https://ter-arkhiv.ru/0040-3660/article/viewFile/31983/pdf kostenfrei https://doaj.org/toc/0040-3660 Journal toc kostenfrei https://doaj.org/toc/2309-5342 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 88 2016 4 75-81 |
| allfieldsGer |
(DE-627)DOAJ045754519 (DE-599)DOAJ6ebba4cee6dc49899868fa5ccff77a9b DE-627 ger DE-627 rakwb rus D N Andreev verfasserin aut The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To evaluate the efficiency and safety of two eradication therapy (ET) regimens for Helicobacter pylori infection in patients with concomitant chronic hepatitis C (CHC) in relation to the stage of liver fibrosis (LF). Subjects and methods. A prospective clinical trial was conducted in parallel groups. Group 1 included 50 HCV-negative patients with H. pylori-associated peptic ulcer of the stomach or duodenum; Group 2 consisted of 50 HCV-positive patients with H. pylori-associated peptic ulcer of the stomach or duodenum concurrent with CHC. Each group was divided in 2 subgroups according to the used triple ET (a proton pump inhibitor (PPI) in a standard dose + amoxicillin 1000 mg twice daily + clarithromycin 500 mg twice daily for 10 days) or sequential therapy (PPI in a standard dose + amoxicillin 1000 mg twice daily within the first 5 days and then PPI in a standard dose + clarithromycin 500 mg twice daily + metronidazole 500 mg twice daily for the next 5 days). LF was assessed using indirect elastometry. The efficiency of ET was evaluated by a breath test (after 4 weeks) and an analysis depending on intention-to-treat (ITT) and per-protocol (PP) treatments. A patients recorded adverse events in specially developed diaries. Results. The efficiency of ET was 74% (ITT) and 80.4% (PP) in Group 1 and 76 (ITT) and 79.1% (PP) in Group 2. Both groups displayed a tendency towards an 11.9—12.4% increase in the efficiency of the sequential therapy versus the classical triple (PP) one. The rate of totally found side effects was 20% in Group 1 and 28% in Group 2. During sequential therapy, the rate of side effects was lower than that during the classical one. The efficiency of ET did not significantly depend on the stage of LF. Only the presence of concomitant type 2 diabetes mellitus and the use of macrolides (12 months before treatment) significantly lowered the efficiency of ET (OR 0,21; 95% CI 0,06—0,69, p=0,0102 and OR 0,27 95% CI 0,08—0,9, p=0,0342). LF regardless of its magnitude significantly determined the risk of adverse events during ET (OR 3,33 95% CI 1,19—9,31, p=0,0217). A group at the highest risk of adverse events included patients with liver cirrhosis (OR 4,87; 95% CI 1,01—23,5, p=0,0492). Conclusion. It is appropriate to prescribe a sequential ET regimen as more effective and safe for patients with concomitant CHC during therapy for H. pylori infection-associated diseases. LF increases the risk of adverse events during ET. helicobacter pylori peptic ulcer hcv hepatitis c liver fibrosis liver cirrhosis anti-helicobacter pylori therapy adverse events Medicine R I V Maev verfasserin aut Yu A Kucheryavyi verfasserin aut D T Dicheva verfasserin aut E V Partsvania-vinogradova verfasserin aut In Терапевтический архив "Consilium Medicum" Publishing house, 2018 88(2016), 4, Seite 75-81 (DE-627)1760620270 23095342 nnns volume:88 year:2016 number:4 pages:75-81 https://doaj.org/article/6ebba4cee6dc49899868fa5ccff77a9b kostenfrei https://ter-arkhiv.ru/0040-3660/article/viewFile/31983/pdf kostenfrei https://doaj.org/toc/0040-3660 Journal toc kostenfrei https://doaj.org/toc/2309-5342 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 88 2016 4 75-81 |
| allfieldsSound |
(DE-627)DOAJ045754519 (DE-599)DOAJ6ebba4cee6dc49899868fa5ccff77a9b DE-627 ger DE-627 rakwb rus D N Andreev verfasserin aut The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C 2016 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Aim. To evaluate the efficiency and safety of two eradication therapy (ET) regimens for Helicobacter pylori infection in patients with concomitant chronic hepatitis C (CHC) in relation to the stage of liver fibrosis (LF). Subjects and methods. A prospective clinical trial was conducted in parallel groups. Group 1 included 50 HCV-negative patients with H. pylori-associated peptic ulcer of the stomach or duodenum; Group 2 consisted of 50 HCV-positive patients with H. pylori-associated peptic ulcer of the stomach or duodenum concurrent with CHC. Each group was divided in 2 subgroups according to the used triple ET (a proton pump inhibitor (PPI) in a standard dose + amoxicillin 1000 mg twice daily + clarithromycin 500 mg twice daily for 10 days) or sequential therapy (PPI in a standard dose + amoxicillin 1000 mg twice daily within the first 5 days and then PPI in a standard dose + clarithromycin 500 mg twice daily + metronidazole 500 mg twice daily for the next 5 days). LF was assessed using indirect elastometry. The efficiency of ET was evaluated by a breath test (after 4 weeks) and an analysis depending on intention-to-treat (ITT) and per-protocol (PP) treatments. A patients recorded adverse events in specially developed diaries. Results. The efficiency of ET was 74% (ITT) and 80.4% (PP) in Group 1 and 76 (ITT) and 79.1% (PP) in Group 2. Both groups displayed a tendency towards an 11.9—12.4% increase in the efficiency of the sequential therapy versus the classical triple (PP) one. The rate of totally found side effects was 20% in Group 1 and 28% in Group 2. During sequential therapy, the rate of side effects was lower than that during the classical one. The efficiency of ET did not significantly depend on the stage of LF. Only the presence of concomitant type 2 diabetes mellitus and the use of macrolides (12 months before treatment) significantly lowered the efficiency of ET (OR 0,21; 95% CI 0,06—0,69, p=0,0102 and OR 0,27 95% CI 0,08—0,9, p=0,0342). LF regardless of its magnitude significantly determined the risk of adverse events during ET (OR 3,33 95% CI 1,19—9,31, p=0,0217). A group at the highest risk of adverse events included patients with liver cirrhosis (OR 4,87; 95% CI 1,01—23,5, p=0,0492). Conclusion. It is appropriate to prescribe a sequential ET regimen as more effective and safe for patients with concomitant CHC during therapy for H. pylori infection-associated diseases. LF increases the risk of adverse events during ET. helicobacter pylori peptic ulcer hcv hepatitis c liver fibrosis liver cirrhosis anti-helicobacter pylori therapy adverse events Medicine R I V Maev verfasserin aut Yu A Kucheryavyi verfasserin aut D T Dicheva verfasserin aut E V Partsvania-vinogradova verfasserin aut In Терапевтический архив "Consilium Medicum" Publishing house, 2018 88(2016), 4, Seite 75-81 (DE-627)1760620270 23095342 nnns volume:88 year:2016 number:4 pages:75-81 https://doaj.org/article/6ebba4cee6dc49899868fa5ccff77a9b kostenfrei https://ter-arkhiv.ru/0040-3660/article/viewFile/31983/pdf kostenfrei https://doaj.org/toc/0040-3660 Journal toc kostenfrei https://doaj.org/toc/2309-5342 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 88 2016 4 75-81 |
| language |
Russian |
| source |
In Терапевтический архив 88(2016), 4, Seite 75-81 volume:88 year:2016 number:4 pages:75-81 |
| sourceStr |
In Терапевтический архив 88(2016), 4, Seite 75-81 volume:88 year:2016 number:4 pages:75-81 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
helicobacter pylori peptic ulcer hcv hepatitis c liver fibrosis liver cirrhosis anti-helicobacter pylori therapy adverse events Medicine R |
| isfreeaccess_bool |
true |
| container_title |
Терапевтический архив |
| authorswithroles_txt_mv |
D N Andreev @@aut@@ I V Maev @@aut@@ Yu A Kucheryavyi @@aut@@ D T Dicheva @@aut@@ E V Partsvania-vinogradova @@aut@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
1760620270 |
| id |
DOAJ045754519 |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ045754519</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308095232.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2016 xx |||||o 00| ||rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ045754519</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ6ebba4cee6dc49899868fa5ccff77a9b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">D N Andreev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim. To evaluate the efficiency and safety of two eradication therapy (ET) regimens for Helicobacter pylori infection in patients with concomitant chronic hepatitis C (CHC) in relation to the stage of liver fibrosis (LF). Subjects and methods. A prospective clinical trial was conducted in parallel groups. Group 1 included 50 HCV-negative patients with H. pylori-associated peptic ulcer of the stomach or duodenum; Group 2 consisted of 50 HCV-positive patients with H. pylori-associated peptic ulcer of the stomach or duodenum concurrent with CHC. Each group was divided in 2 subgroups according to the used triple ET (a proton pump inhibitor (PPI) in a standard dose + amoxicillin 1000 mg twice daily + clarithromycin 500 mg twice daily for 10 days) or sequential therapy (PPI in a standard dose + amoxicillin 1000 mg twice daily within the first 5 days and then PPI in a standard dose + clarithromycin 500 mg twice daily + metronidazole 500 mg twice daily for the next 5 days). LF was assessed using indirect elastometry. The efficiency of ET was evaluated by a breath test (after 4 weeks) and an analysis depending on intention-to-treat (ITT) and per-protocol (PP) treatments. A patients recorded adverse events in specially developed diaries. Results. The efficiency of ET was 74% (ITT) and 80.4% (PP) in Group 1 and 76 (ITT) and 79.1% (PP) in Group 2. Both groups displayed a tendency towards an 11.9—12.4% increase in the efficiency of the sequential therapy versus the classical triple (PP) one. The rate of totally found side effects was 20% in Group 1 and 28% in Group 2. During sequential therapy, the rate of side effects was lower than that during the classical one. The efficiency of ET did not significantly depend on the stage of LF. Only the presence of concomitant type 2 diabetes mellitus and the use of macrolides (12 months before treatment) significantly lowered the efficiency of ET (OR 0,21; 95% CI 0,06—0,69, p=0,0102 and OR 0,27 95% CI 0,08—0,9, p=0,0342). LF regardless of its magnitude significantly determined the risk of adverse events during ET (OR 3,33 95% CI 1,19—9,31, p=0,0217). A group at the highest risk of adverse events included patients with liver cirrhosis (OR 4,87; 95% CI 1,01—23,5, p=0,0492). Conclusion. It is appropriate to prescribe a sequential ET regimen as more effective and safe for patients with concomitant CHC during therapy for H. pylori infection-associated diseases. LF increases the risk of adverse events during ET.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">helicobacter pylori</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">peptic ulcer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hcv</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hepatitis c</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">liver fibrosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">liver cirrhosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anti-helicobacter pylori therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">adverse events</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I V Maev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yu A Kucheryavyi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D T Dicheva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E V Partsvania-vinogradova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Терапевтический архив</subfield><subfield code="d">"Consilium Medicum" Publishing house, 2018</subfield><subfield code="g">88(2016), 4, Seite 75-81</subfield><subfield code="w">(DE-627)1760620270</subfield><subfield code="x">23095342</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:88</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:75-81</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/6ebba4cee6dc49899868fa5ccff77a9b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ter-arkhiv.ru/0040-3660/article/viewFile/31983/pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0040-3660</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2309-5342</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">88</subfield><subfield code="j">2016</subfield><subfield code="e">4</subfield><subfield code="h">75-81</subfield></datafield></record></collection>
|
| author |
D N Andreev |
| spellingShingle |
D N Andreev misc helicobacter pylori misc peptic ulcer misc hcv misc hepatitis c misc liver fibrosis misc liver cirrhosis misc anti-helicobacter pylori therapy misc adverse events misc Medicine misc R The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C |
| authorStr |
D N Andreev |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760620270 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
23095342 |
| topic_title |
The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C helicobacter pylori peptic ulcer hcv hepatitis c liver fibrosis liver cirrhosis anti-helicobacter pylori therapy adverse events |
| topic |
misc helicobacter pylori misc peptic ulcer misc hcv misc hepatitis c misc liver fibrosis misc liver cirrhosis misc anti-helicobacter pylori therapy misc adverse events misc Medicine misc R |
| topic_unstemmed |
misc helicobacter pylori misc peptic ulcer misc hcv misc hepatitis c misc liver fibrosis misc liver cirrhosis misc anti-helicobacter pylori therapy misc adverse events misc Medicine misc R |
| topic_browse |
misc helicobacter pylori misc peptic ulcer misc hcv misc hepatitis c misc liver fibrosis misc liver cirrhosis misc anti-helicobacter pylori therapy misc adverse events misc Medicine misc R |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Терапевтический архив |
| hierarchy_parent_id |
1760620270 |
| hierarchy_top_title |
Терапевтический архив |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760620270 |
| title |
The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C |
| ctrlnum |
(DE-627)DOAJ045754519 (DE-599)DOAJ6ebba4cee6dc49899868fa5ccff77a9b |
| title_full |
The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C |
| author_sort |
D N Andreev |
| journal |
Терапевтический архив |
| journalStr |
Терапевтический архив |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
txt |
| container_start_page |
75 |
| author_browse |
D N Andreev I V Maev Yu A Kucheryavyi D T Dicheva E V Partsvania-vinogradova |
| container_volume |
88 |
| format_se |
Elektronische Aufsätze |
| author-letter |
D N Andreev |
| author2-role |
verfasserin |
| title_sort |
efficiency and safety of anti-helicobacter pylori therapy in patients with concomitant chronic hepatitis c |
| title_auth |
The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C |
| abstract |
Aim. To evaluate the efficiency and safety of two eradication therapy (ET) regimens for Helicobacter pylori infection in patients with concomitant chronic hepatitis C (CHC) in relation to the stage of liver fibrosis (LF). Subjects and methods. A prospective clinical trial was conducted in parallel groups. Group 1 included 50 HCV-negative patients with H. pylori-associated peptic ulcer of the stomach or duodenum; Group 2 consisted of 50 HCV-positive patients with H. pylori-associated peptic ulcer of the stomach or duodenum concurrent with CHC. Each group was divided in 2 subgroups according to the used triple ET (a proton pump inhibitor (PPI) in a standard dose + amoxicillin 1000 mg twice daily + clarithromycin 500 mg twice daily for 10 days) or sequential therapy (PPI in a standard dose + amoxicillin 1000 mg twice daily within the first 5 days and then PPI in a standard dose + clarithromycin 500 mg twice daily + metronidazole 500 mg twice daily for the next 5 days). LF was assessed using indirect elastometry. The efficiency of ET was evaluated by a breath test (after 4 weeks) and an analysis depending on intention-to-treat (ITT) and per-protocol (PP) treatments. A patients recorded adverse events in specially developed diaries. Results. The efficiency of ET was 74% (ITT) and 80.4% (PP) in Group 1 and 76 (ITT) and 79.1% (PP) in Group 2. Both groups displayed a tendency towards an 11.9—12.4% increase in the efficiency of the sequential therapy versus the classical triple (PP) one. The rate of totally found side effects was 20% in Group 1 and 28% in Group 2. During sequential therapy, the rate of side effects was lower than that during the classical one. The efficiency of ET did not significantly depend on the stage of LF. Only the presence of concomitant type 2 diabetes mellitus and the use of macrolides (12 months before treatment) significantly lowered the efficiency of ET (OR 0,21; 95% CI 0,06—0,69, p=0,0102 and OR 0,27 95% CI 0,08—0,9, p=0,0342). LF regardless of its magnitude significantly determined the risk of adverse events during ET (OR 3,33 95% CI 1,19—9,31, p=0,0217). A group at the highest risk of adverse events included patients with liver cirrhosis (OR 4,87; 95% CI 1,01—23,5, p=0,0492). Conclusion. It is appropriate to prescribe a sequential ET regimen as more effective and safe for patients with concomitant CHC during therapy for H. pylori infection-associated diseases. LF increases the risk of adverse events during ET. |
| abstractGer |
Aim. To evaluate the efficiency and safety of two eradication therapy (ET) regimens for Helicobacter pylori infection in patients with concomitant chronic hepatitis C (CHC) in relation to the stage of liver fibrosis (LF). Subjects and methods. A prospective clinical trial was conducted in parallel groups. Group 1 included 50 HCV-negative patients with H. pylori-associated peptic ulcer of the stomach or duodenum; Group 2 consisted of 50 HCV-positive patients with H. pylori-associated peptic ulcer of the stomach or duodenum concurrent with CHC. Each group was divided in 2 subgroups according to the used triple ET (a proton pump inhibitor (PPI) in a standard dose + amoxicillin 1000 mg twice daily + clarithromycin 500 mg twice daily for 10 days) or sequential therapy (PPI in a standard dose + amoxicillin 1000 mg twice daily within the first 5 days and then PPI in a standard dose + clarithromycin 500 mg twice daily + metronidazole 500 mg twice daily for the next 5 days). LF was assessed using indirect elastometry. The efficiency of ET was evaluated by a breath test (after 4 weeks) and an analysis depending on intention-to-treat (ITT) and per-protocol (PP) treatments. A patients recorded adverse events in specially developed diaries. Results. The efficiency of ET was 74% (ITT) and 80.4% (PP) in Group 1 and 76 (ITT) and 79.1% (PP) in Group 2. Both groups displayed a tendency towards an 11.9—12.4% increase in the efficiency of the sequential therapy versus the classical triple (PP) one. The rate of totally found side effects was 20% in Group 1 and 28% in Group 2. During sequential therapy, the rate of side effects was lower than that during the classical one. The efficiency of ET did not significantly depend on the stage of LF. Only the presence of concomitant type 2 diabetes mellitus and the use of macrolides (12 months before treatment) significantly lowered the efficiency of ET (OR 0,21; 95% CI 0,06—0,69, p=0,0102 and OR 0,27 95% CI 0,08—0,9, p=0,0342). LF regardless of its magnitude significantly determined the risk of adverse events during ET (OR 3,33 95% CI 1,19—9,31, p=0,0217). A group at the highest risk of adverse events included patients with liver cirrhosis (OR 4,87; 95% CI 1,01—23,5, p=0,0492). Conclusion. It is appropriate to prescribe a sequential ET regimen as more effective and safe for patients with concomitant CHC during therapy for H. pylori infection-associated diseases. LF increases the risk of adverse events during ET. |
| abstract_unstemmed |
Aim. To evaluate the efficiency and safety of two eradication therapy (ET) regimens for Helicobacter pylori infection in patients with concomitant chronic hepatitis C (CHC) in relation to the stage of liver fibrosis (LF). Subjects and methods. A prospective clinical trial was conducted in parallel groups. Group 1 included 50 HCV-negative patients with H. pylori-associated peptic ulcer of the stomach or duodenum; Group 2 consisted of 50 HCV-positive patients with H. pylori-associated peptic ulcer of the stomach or duodenum concurrent with CHC. Each group was divided in 2 subgroups according to the used triple ET (a proton pump inhibitor (PPI) in a standard dose + amoxicillin 1000 mg twice daily + clarithromycin 500 mg twice daily for 10 days) or sequential therapy (PPI in a standard dose + amoxicillin 1000 mg twice daily within the first 5 days and then PPI in a standard dose + clarithromycin 500 mg twice daily + metronidazole 500 mg twice daily for the next 5 days). LF was assessed using indirect elastometry. The efficiency of ET was evaluated by a breath test (after 4 weeks) and an analysis depending on intention-to-treat (ITT) and per-protocol (PP) treatments. A patients recorded adverse events in specially developed diaries. Results. The efficiency of ET was 74% (ITT) and 80.4% (PP) in Group 1 and 76 (ITT) and 79.1% (PP) in Group 2. Both groups displayed a tendency towards an 11.9—12.4% increase in the efficiency of the sequential therapy versus the classical triple (PP) one. The rate of totally found side effects was 20% in Group 1 and 28% in Group 2. During sequential therapy, the rate of side effects was lower than that during the classical one. The efficiency of ET did not significantly depend on the stage of LF. Only the presence of concomitant type 2 diabetes mellitus and the use of macrolides (12 months before treatment) significantly lowered the efficiency of ET (OR 0,21; 95% CI 0,06—0,69, p=0,0102 and OR 0,27 95% CI 0,08—0,9, p=0,0342). LF regardless of its magnitude significantly determined the risk of adverse events during ET (OR 3,33 95% CI 1,19—9,31, p=0,0217). A group at the highest risk of adverse events included patients with liver cirrhosis (OR 4,87; 95% CI 1,01—23,5, p=0,0492). Conclusion. It is appropriate to prescribe a sequential ET regimen as more effective and safe for patients with concomitant CHC during therapy for H. pylori infection-associated diseases. LF increases the risk of adverse events during ET. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
4 |
| title_short |
The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C |
| url |
https://doaj.org/article/6ebba4cee6dc49899868fa5ccff77a9b https://ter-arkhiv.ru/0040-3660/article/viewFile/31983/pdf https://doaj.org/toc/0040-3660 https://doaj.org/toc/2309-5342 |
| remote_bool |
true |
| author2 |
I V Maev Yu A Kucheryavyi D T Dicheva E V Partsvania-vinogradova |
| author2Str |
I V Maev Yu A Kucheryavyi D T Dicheva E V Partsvania-vinogradova |
| ppnlink |
1760620270 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| up_date |
2024-07-03T16:50:12.291Z |
| _version_ |
1803577366720544768 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ045754519</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308095232.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2016 xx |||||o 00| ||rus c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ045754519</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ6ebba4cee6dc49899868fa5ccff77a9b</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">D N Andreev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="4"><subfield code="a">The efficiency and safety of anti-Helicobacter pylori therapy in patients with concomitant chronic hepatitis C</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aim. To evaluate the efficiency and safety of two eradication therapy (ET) regimens for Helicobacter pylori infection in patients with concomitant chronic hepatitis C (CHC) in relation to the stage of liver fibrosis (LF). Subjects and methods. A prospective clinical trial was conducted in parallel groups. Group 1 included 50 HCV-negative patients with H. pylori-associated peptic ulcer of the stomach or duodenum; Group 2 consisted of 50 HCV-positive patients with H. pylori-associated peptic ulcer of the stomach or duodenum concurrent with CHC. Each group was divided in 2 subgroups according to the used triple ET (a proton pump inhibitor (PPI) in a standard dose + amoxicillin 1000 mg twice daily + clarithromycin 500 mg twice daily for 10 days) or sequential therapy (PPI in a standard dose + amoxicillin 1000 mg twice daily within the first 5 days and then PPI in a standard dose + clarithromycin 500 mg twice daily + metronidazole 500 mg twice daily for the next 5 days). LF was assessed using indirect elastometry. The efficiency of ET was evaluated by a breath test (after 4 weeks) and an analysis depending on intention-to-treat (ITT) and per-protocol (PP) treatments. A patients recorded adverse events in specially developed diaries. Results. The efficiency of ET was 74% (ITT) and 80.4% (PP) in Group 1 and 76 (ITT) and 79.1% (PP) in Group 2. Both groups displayed a tendency towards an 11.9—12.4% increase in the efficiency of the sequential therapy versus the classical triple (PP) one. The rate of totally found side effects was 20% in Group 1 and 28% in Group 2. During sequential therapy, the rate of side effects was lower than that during the classical one. The efficiency of ET did not significantly depend on the stage of LF. Only the presence of concomitant type 2 diabetes mellitus and the use of macrolides (12 months before treatment) significantly lowered the efficiency of ET (OR 0,21; 95% CI 0,06—0,69, p=0,0102 and OR 0,27 95% CI 0,08—0,9, p=0,0342). LF regardless of its magnitude significantly determined the risk of adverse events during ET (OR 3,33 95% CI 1,19—9,31, p=0,0217). A group at the highest risk of adverse events included patients with liver cirrhosis (OR 4,87; 95% CI 1,01—23,5, p=0,0492). Conclusion. It is appropriate to prescribe a sequential ET regimen as more effective and safe for patients with concomitant CHC during therapy for H. pylori infection-associated diseases. LF increases the risk of adverse events during ET.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">helicobacter pylori</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">peptic ulcer</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hcv</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hepatitis c</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">liver fibrosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">liver cirrhosis</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">anti-helicobacter pylori therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">adverse events</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">I V Maev</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Yu A Kucheryavyi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">D T Dicheva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E V Partsvania-vinogradova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Терапевтический архив</subfield><subfield code="d">"Consilium Medicum" Publishing house, 2018</subfield><subfield code="g">88(2016), 4, Seite 75-81</subfield><subfield code="w">(DE-627)1760620270</subfield><subfield code="x">23095342</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:88</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:75-81</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/6ebba4cee6dc49899868fa5ccff77a9b</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://ter-arkhiv.ru/0040-3660/article/viewFile/31983/pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0040-3660</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2309-5342</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">88</subfield><subfield code="j">2016</subfield><subfield code="e">4</subfield><subfield code="h">75-81</subfield></datafield></record></collection>
|
| score |
7.402643 |